Kyverna Therapeutics, Inc. Common Stock (KYTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $319.27M
Last updated: Nov 17, 2026 at 11:06 AM ET
Kyverna Therapeutics, Inc. Common Stock (KYTX) Competitors
The companies most similar to Kyverna Therapeutics, Inc. Common Stock are Immuneering (IMRX), Keros Therapeutics (KROS) and Gyre Therapeutics (GYRE). By market cap, Kyverna Therapeutics, Inc. Common Stock ranks 10th of the 13 companies on this page; Zevra Therapeutics (ZVRA) is the largest at $540.30M.
Peer Comparison
KYTX's ROIC of -81.5% is below the peer median of -30.6%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $319.27M | N/A | N/A | 0.0% | -81.5% | 0.0% | 0.00% |
| Immuneering Corp (IMRX) | $240.27M | N/A | N/A | 0.0% | N/A | -99.8% | 0.00% |
| Keros Therapeutics Inc (KROS) | $202.13M | N/A | 4.9x | -151.4% | N/A | 180.5% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Zevra Therapeutics Inc. (ZVRA) | $540.30M | 11.6x | 3.7x | 52.8% | N/A | 44.9% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Candel Therapeutics Inc (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Inovio Pharmaceuticals Inc (INO) | $267.85M | N/A | 462.0x | 0.0% | N/A | -100.0% | 0.00% |
| Peer median | $446.72M | 11.6x | 4.4x | 0.0% | -30.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Kyverna Therapeutics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Immuneering Corp (IMRX) | Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its... | IMRX competitors |
| Keros Therapeutics Inc (KROS) | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery... | KROS competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Zevra Therapeutics Inc. (ZVRA) | Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions... | ZVRA competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Candel Therapeutics Inc (CADL) | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform... | CADL competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Inovio Pharmaceuticals Inc (INO) | Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development... | INO competitors |
Frequently Asked Questions About KYTX
Who are Kyverna Therapeutics, Inc. Common Stock's main competitors?
The companies most similar to Kyverna Therapeutics, Inc. Common Stock include Immuneering (IMRX), Keros Therapeutics (KROS), Gyre Therapeutics (GYRE), Avalo Therapeutics (AVTX) and Indaptus Therapeutics (INDP), listed from the closest match.
Who is Kyverna Therapeutics, Inc. Common Stock's biggest competitor?
Zevra Therapeutics (ZVRA) is the largest of the similar companies at $540.30M; Immuneering (IMRX) is the closest match by business profile, size, sector and industry.
How does KYTX stock compare with its competitors?
KYTX's net margin is 0.0% against a peer median of 0.0%.
Which of Kyverna Therapeutics, Inc. Common Stock's competitors pays a higher dividend?
Kyverna Therapeutics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Kyverna Therapeutics, Inc. Common Stock bigger than its competitors?
No. Kyverna Therapeutics, Inc. Common Stock is 10th by market cap among the 13 companies on this page; the largest is Zevra Therapeutics (ZVRA) at $540.30M.
KYTX pages: Overview, Earnings, Forecast, Financials, Competitors